全文获取类型
收费全文 | 296篇 |
免费 | 23篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 10篇 |
妇产科学 | 2篇 |
基础医学 | 57篇 |
口腔科学 | 4篇 |
临床医学 | 15篇 |
内科学 | 96篇 |
皮肤病学 | 10篇 |
神经病学 | 5篇 |
特种医学 | 10篇 |
外科学 | 37篇 |
综合类 | 2篇 |
预防医学 | 8篇 |
眼科学 | 6篇 |
药学 | 14篇 |
肿瘤学 | 49篇 |
出版年
2022年 | 5篇 |
2021年 | 11篇 |
2019年 | 9篇 |
2018年 | 8篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 15篇 |
2014年 | 11篇 |
2013年 | 8篇 |
2012年 | 10篇 |
2011年 | 16篇 |
2010年 | 5篇 |
2009年 | 13篇 |
2008年 | 12篇 |
2007年 | 15篇 |
2006年 | 6篇 |
2005年 | 15篇 |
2004年 | 11篇 |
2003年 | 10篇 |
2002年 | 20篇 |
2001年 | 7篇 |
2000年 | 11篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 6篇 |
1995年 | 6篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 6篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 2篇 |
1969年 | 1篇 |
1968年 | 2篇 |
1967年 | 3篇 |
1966年 | 1篇 |
排序方式: 共有326条查询结果,搜索用时 31 毫秒
1.
2.
Daisuke Kubota Takanori Kanai Fumiro Yui Tomoko Matsumoto Takahiro Kawamura Yasuhiro Itsui Eriko Okada Seishin Chin Shinya Ooka Masakazu Nagahori Kiichiro Tsuchiya Akihiro Araki Naoya Sakamoto Tatsuya Miyata Mamoru Watanabe 《Nihon Shokakibyo Gakkai zasshi》2007,104(1):42-46
A 44-year-old women developed marked myopathy one year earlier, when she was treated with intravenous prednisolone for acute severe exacerbation of ulcerative colitis. When she was admitted to our hospital for another severe exacerbation, intravenous cyclosporine A was administered as monotherapy because she could not tolerate corticosteroid. The treatment was successful and she obtained complete remission. Cyclosporine A monotherapy is considered to be a valuable alternative to proctocolectomy for severe ulcerative colitis patients who cannot tolerate corticosteroid. 相似文献
3.
4.
Shouhei Nagaoka Mitsuyuki Nakamura Akiko Senuma Akiko Sekiguchi 《Nihon Rinshō Men'eki Gakkai kaishi》2005,28(6):389-397
The efficacy and safety of MTX in active RA were evaluated based on patient medical records. The study population consisted of 460 patients with active RA who had received no prior MTX therapy and started it at our hospital between August 1998 and December 2003 (80 men and 380 women with a mean age of 59.3 years). After 24 weeks of MTX therapy, 61.3% of patients showed a 20% improvement, and 30.4% achieved a 50% improvement according to the ACR criteria. The cumulative rate of patients who continued MTX therapy for 48 weeks was 0.567. During the observation period, 260 patients (56.5%) experienced 304 adverse reactions. 52 patients (11.3%) discontinued treatment because of adverse reactions, and 10 patients (2.2%) died. The adverse reactions that occurred in at least 1% of patients were: abnormal hepatic function (31.7%), infection (6.1%), gastrointestinal symptoms (5.0%), stomatitis (3.9%), hematological abnormalities (3.5%), fracture (3.5%), malignant tumor (2.6%), interstitial pneumonia (2.0%), cerebrovascular or cardiovascular disorder (2.0%), headache (1.7%), eruption (1.3%), and alopecia (1.1%). Adverse reactions were more common in the elderly and patients with advanced stage disease. This study reaffirms the therapeutic benefit of MTX, but suggests that careful monitoring is of great importance. 相似文献
5.
Obuse C Yang H Nozaki N Goto S Okazaki T Yoda K 《Genes to cells : devoted to molecular & cellular mechanisms》2004,9(2):105-120
CENP-A, a centromere-specific histone H3, is conserved throughout eukaryotes, and formation of CENP-A chromatin defines the active centromere region. Here, we report the isolation of CENP-A chromatin from HeLa interphase nuclei by chromatin immunoprecipitation using anti-CENP-A monoclonal antibody, and systematic identification of its components by mass spectrometric analyses. The isolated chromatin contained CENP-B, CENP-C, CENP-H, CENP-I/hMis 6 and hMis 12 as well as CENP-A, suggesting that the isolated chromatin may represent the centromere complex (CEN-complex). Mass spectrometric analyses of the CEN-complex identified approximately 40 proteins, including the previously reported centromere proteins and the proteins of unknown function. In addition, we unexpectedly identified a series of proteins previously reported to be related to functions other than chromosome segregation, such as uvDDB-1, XAP8, hSNF2H, FACTp180, FACTp80/SSRP1, polycomb group proteins (BMI-1, RING1, RNF2, HPC3 and PHP2), KNL5 and racGAP. We found that uvDDB-1 was actually localized to the centromeric region throughout cell cycle, while BMI-1 was transiently co-localized with the centromeres in interphase. These results give us new insights into the architecture, dynamics and function of centromeric chromatin in interphase nuclei, which might reflect regulation of cell proliferation and differentiation. 相似文献
6.
Shuaizhang Li Jinghua Zhao Ruili Huang Jameson Travers Carleen Klumpp-Thomas Wenbo Yu Alexander D. MacKerell Jr. Srilatha Sakamuru Masato Ooka Fengtian Xue Nisha S. Sipes Jui-Hua Hsieh Kristen Ryan Anton Simeonov Michael F. Santillo Menghang Xia 《Environmental health perspectives》2021,129(4)
Background: Inhibition of acetylcholinesterase (AChE), a biomarker of organophosphorous and carbamate exposure in environmental and occupational human health, has been commonly used to identify potential safety liabilities. So far, many environmental chemicals, including drug candidates, food additives, and industrial chemicals, have not been thoroughly evaluated for their inhibitory effects on AChE activity. AChE inhibitors can have therapeutic applications (e.g., tacrine and donepezil) or neurotoxic consequences (e.g., insecticides and nerve agents).Objectives: The objective of the current study was to identify environmental chemicals that inhibit AChE activity using in vitro and in silico models.Methods: To identify AChE inhibitors rapidly and efficiently, we have screened the Toxicology in the 21st Century (Tox21) 10K compound library in a quantitative high-throughput screening (qHTS) platform by using the homogenous cell-based AChE inhibition assay and enzyme-based AChE inhibition assays (with or without microsomes). AChE inhibitors identified from the primary screening were further tested in monolayer or spheroid formed by SH-SY5Y and neural stem cell models. The inhibition and binding modes of these identified compounds were studied with time-dependent enzyme-based AChE inhibition assay and molecular docking, respectively.Results: A group of known AChE inhibitors, such as donepezil, ambenonium dichloride, and tacrine hydrochloride, as well as many previously unreported AChE inhibitors, such as chelerythrine chloride and cilostazol, were identified in this study. Many of these compounds, such as pyrazophos, phosalone, and triazophos, needed metabolic activation. This study identified both reversible (e.g., donepezil and tacrine) and irreversible inhibitors (e.g., chlorpyrifos and bromophos-ethyl). Molecular docking analyses were performed to explain the relative inhibitory potency of selected compounds.Conclusions: Our tiered qHTS approach allowed us to generate a robust and reliable data set to evaluate large sets of environmental compounds for their AChE inhibitory activity. https://doi.org/10.1289/EHP6993 相似文献
7.
Suda A Nagaoka S Ohono S Ideguchi H Soga T Ishigatsubo Y 《Modern rheumatology / the Japan Rheumatism Association》2008,18(6):609-614
We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a
first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical
records of 86 patients with active RA who began to receive bucillamine at Yokohama Minami Kyosai Hospital between January
1998 and July 2004. The efficacy of treatments was compared based on rates of achievement of 20, 50, and 70% improvement in
ACR core set 6 months after initiation of the therapy. In the group administered bucillamine as a first-line DMARD (18 patients),
44.4, 22.2, and 11.1% of patients achieved ACR 20, 50, 70, respectively, while 56.5, 34.1, and 19.5% achieved ACR 20, 50,
70, respectively, in the group administered bucillamine following switching from MTX (46 patients), and 53.3, 33.3, and 13.3%
achieved ACR 20, 50, and 70, respectively, in the group administered bucillamine following switching from Sulfasalazine (SSZ)
(15 patients). The rates of achievements of ACR 20, 50, 70 did not differ statistically between the three groups and there
was no increase in risk of serious adverse effects related to previous DMARDs. The usefulness of bucillamine as a second-line
DMARD was demonstrated. 相似文献
8.
Takeshi Asano Hidehiko Narazaki Kiyohiko Kaizu Shouhei Matsukawa Yuki Takema‐Tochikubo Shuichi Fujii Nobuyuki Saitoh Kunihiko Mashiko Osamu Fujino 《Pediatrics international》2015,57(5):988-990
Although thrombotic thrombocytopenic purpura (TTP) is rare, early diagnosis and treatment are important for decreasing the mortality rate. Acquired vitamin B12 deficiency is frequently overlooked because of its rarity in developed countries, particularly in children and adolescents. The hematological changes in vitamin B12 deficiency present as megaloblastic anemia, increased lactate dehydrogenase, vasoconstriction, increased platelet aggregation, and abnormal activation of the coagulation followed by microangiopathy as well as neutropenia and thrombocytopenia. We report herein the case of a 15‐year‐old girl who had been neglected, which might have caused pseudo‐TTP through malnutrition, particularly vitamin B12 deficiency. When we encounter cases of TTP in children, clinicians must be aware of the possibility of malnutrition, particularly with vitamin B12 deficiency, even in developed countries, and investigate the cause of malnutrition including neglect. 相似文献
9.
N Satozawa K Takezawa T Miwa S Takahashi M Hayakawa H Ooka 《Growth hormone & IGF research》2000,10(4):187-192
Antidiuretic actions induced by two growth hormone (GH) isoforms (20 K- and 22 K-hGH; 0.2 and 2.0 mg/kg) were evaluated in rats, as fluid retention may cause oedema, one of the adverse effects of GH. Both GH isoforms (2.0 mg/kg) suppressed urine excretion in hypophysectomized rats (P< 0.01), but only the 22 K-hGH isoform (2.0 mg/kg) suppressed urine excretion in intact rats (P< 0.01). In addition, prolactin (PRL) suppressed urine excretion in intact rats (P< 0.05). In conclusion, 20 K-hGH has less potency in causing urine retention than 22 K-hGH and since 20 K-hGH is missing 15 amino acids found in 22 K-hGH, these amino acids may be important for the antidiuretic action of GH. Since prolactin suppressed urine excretion, a part of the antidiuretic action of GH may be related to PRL-R activation. 相似文献
10.
OBJECTIVES: We studied the difference between effects of therapeutic dose and sub-therapeutic dose of gliclazide on the glucose-induced insulin secretion. METHODS: The normal rat pancreas was isolated and perfused with Krebs-Ringer buffer containing 1-14 mmol/l glucose. Influcences of 0.25 and 2.5 microg/ml gliclazide on the glucose concentration-insulin secretion curve was examined. RESULTS: Gliclazide at 0.25 microg/ml significantly potentiated 5-8 mmol/l glucose-induced insulin secretion (2.5 +/- 0.5 vs 1.0 +/- 0.3 mU for 15 min at 6.5 mmol/l glucose, P<0.01), but did not give influence on either 1-3 or 10-14 mmol/l glucose-induced insulin secretion. The glucose concentration, at which half-maximal insulin secretion was observed, was lower with gliclazide (5.9 mmol/l) than in the control (7.5 mmol/l). Gliclazide at 2.5 microg/ml markedly increased the maximally glucose-stimulated insulin secretion from 3.9 +/- 0.5 mU for 15 min in the control to 6.6 +/- 0.7 mU for 15 min (P<0.01). The half-maximal insulin secretion was observed at a lower glucose concentration (5.0 mmol/l) than in the absence of gliclazide. CONCLUSION: Gliclazide in sub-therapeutically low dose has different effects on insulin secretion from in therapeutic dose, namely sharpens the insulin secretion sensitivity to glucose with no influence on the maximal insulin secretion. It is possible that low doses of gliclazide might be of interest in some type 2 diabetics whose main pathophysiology is the blunting of insulin secretion response to hyperglycemia. 相似文献